Teladoc Health trades near lows despite strong cash flow; potential upside if key segments stabilize.

Teladoc Health's stock is near multi-year lows as the market prices in significant challenges, mainly due to BetterHelp's rapid decline. However, the company's Integrated Care segment shows improving margins and growing revenue per member, offering some stability. The stock is undervalued, trading at just 7–8 times expected free cash flow, suggesting substantial upside potential if Integrated Care remains stable and BetterHelp successfully transitions to insurance. Analysts estimate a fair value price range of $9–$21, much higher than current levels, indicating a possible investment opportunity if these conditions hold.